Merck May Consider Settling Some Vioxx Suits
This article was originally published in The Pink Sheet Daily
Executive Summary
Representing a shift in legal strategy, Merck may re-evaluate cases involving patients who took Vioxx for long periods of time and had few risk factors for heart disease.
You may also be interested in...
Merck May Need To Rethink Vioxx Defense Strategy Following Surprise Loss
Firm is hit with $31 mil. fine in death of man with many risk factors who took rofecoxib for one week.
Merck May Need To Rethink Vioxx Defense Strategy Following Surprise Loss
Firm is hit with $31 mil. fine in death of man with many risk factors who took rofecoxib for one week.
Merck Cleared In Second Vioxx Product Liability Case
Atlantic City, N.J. state court verdict clears Merck of allegations the drug maker failed to warn patients of risks associated with the use of Vioxx.